Search Immortality Topics:



Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial

Posted: November 7, 2021 at 1:41 am

MIAMI, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the selection of Biorasi LLC (“Biorasi”) as its clinical research organization (CRO) to help conduct its Phase 2 clinical trial evaluating Lomecel-B infusion in Alzheimer’s Disease (AD) subjects.

View original post here:
Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial

Recommendation and review posted by Fredricko